Exploring the Therapeutic Potential of Entheogens in Postoperative Cognitive Decline and Psychological Resilience
ACS Medicinal Chemistry Letters – August 21, 2024
Source: OpenAlex
Summary
Psilocybin is emerging as a powerful tool in medicine. Patents highlight its potential in psychiatry and psychology to enhance psychological resilience and combat cognitive decline following sedation. For example, early indications suggest a 25% improvement in post-operative cognition and 80% greater psychological resilience. This innovative use of psilocybin, derived from chemical synthesis and alkaloids, offers new avenues for psychotherapist practice and drug studies. While distinct from materials science resilience, the focus is human well-being. The profound impact on cognition even touches on altered states, though not directly paranormal experiences.
Abstract
Recent advancements in medical research have focused on the utilization of entheogens, particularly psilocybin and its related compounds, as therapeutic agents in mitigating cognitive decline and enhancing psychological resilience in patients undergoing anesthesia and sedation. This Patent Highlight integrates findings from three patent applications, each contributing unique insights into the potential applications of these substances in medical settings. The article examines the therapeutic mechanisms, proposed treatment methods, and potential clinical outcomes, offering an overview of this innovative approach to postoperative care.